Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: AML, Adult

Interventions: Drug: QN-023a
Drug: Cyclophosphamid
Drug: Fludarabine
Drug: Cytarabine

First Posted Date: 2022-11-01

Last Posted Date: 2024-11-06

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 3

Registration Number: NCT05601466

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Phase 1

Terminated

Conditions: Minimal Residual Disease

Interventions: Drug: QN-030a
Drug: Cyclophosphamid
Drug: Fludarabine
Drug: Cytarabine

First Posted Date: 2022-11-01

Last Posted Date: 2024-11-06

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 1

Registration Number: NCT05601830

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Phase 3

Recruiting

Conditions: Severe Aplastic Anemia

Interventions: Drug: cyclosporine
Procedure: Matched Unrelated Donor Hematopoetic Stem Cell Transplant
Drug: horse anti-thymocyte globulin (ATG)
Procedure: Immunosuppressive Therapy (IST)
Drug: rabbit anti-thymocyte globulin (ATG)
Drug: Methotrexate
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: low-dose total body irradiation (TBI)

First Posted Date: 2022-10-31

Last Posted Date: 2024-11-08

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 234

Registration Number: NCT05600426

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Arkansas, Little Rock, Arkansas, United States

and more 46 locations

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

Phase 2

Recruiting

Conditions: B-cell Lymphoma

Interventions: Biological: Relmacabtagene Autoleucel
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2022-10-21

Last Posted Date: 2024-01-08

Lead Sponsor: Peking University Cancer Hospital & Institute

Target Recruit Count: 20

Registration Number: NCT05590221

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
🇨🇳
Peking University International Hospital, Beijing, Beijing, China

and more 1 locations

Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers

Phase 1

Not yet recruiting

Conditions: Oropharyngeal Cancer
Human Papilloma Virus
Oropharyngeal Cancer, Metastatic
HPV-Related Mucosal Head and Neck Squamous Cell Carcinoma
Refractory Oropharyngeal Squamous Cell Carcinoma
HPV-Related Squamous Cell Carcinoma
Head and Neck Cancer
Oropharyngeal Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer Metastatic

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: NEXI-003 T cells

First Posted Date: 2022-10-17

Last Posted Date: 2024-01-16

Lead Sponsor: NexImmune Inc.

Target Recruit Count: 36

Registration Number: NCT05582590

A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies

Phase 2

Terminated

Conditions: Myeloid Malignancy
Hematologic Malignancy

Interventions: Drug: Ruxolitinib
Drug: Anti-thymocyte globulin (ATG)
Drug: Mesna
Drug: Cyclosporine
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Methotrexate
Radiation: Total Body Irradiation (radiation treatment)
Drug: Busulfan
Drug: Bone marrow infusion
Drug: Thiotepa

First Posted Date: 2022-10-14

Last Posted Date: 2024-07-10

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 3

Registration Number: NCT05579769

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Refractory Multiple Myeloma
Relapsed Multiple Myeloma

Interventions: Biological: Manufactured Anti-BCMA CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2022-10-13

Last Posted Date: 2024-05-03

Lead Sponsor: Thomas Martin, MD

Target Recruit Count: 5

Registration Number: NCT05577000

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL

Phase 2

Recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Cladribine
Drug: Fludarabine

First Posted Date: 2022-10-13

Last Posted Date: 2022-10-13

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 32

Registration Number: NCT05578378

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Pediatric Cancer

Interventions: Drug: Uproleselan
Drug: Fludarabine
Drug: Clofarabine
Drug: Busulfan

First Posted Date: 2022-10-06

Last Posted Date: 2024-08-19

Lead Sponsor: Malika Kapadia

Target Recruit Count: 1

Registration Number: NCT05569512

Locations: 🇺🇸
Helen DeVos Children's Hospital/Spectrum Health, Grand Rapids, Michigan, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

CISH Inactivated TILs in the Treatment of NSCLC

Phase 1

Not yet recruiting

Conditions: Metastatic Non Small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Squamous Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Adenocarcinoma of Lung
Large Cell Lung Cancer

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: CISH Inactivated TIL
Drug: Aldesleukin
Drug: Pembrolizumab

First Posted Date: 2022-10-04

Last Posted Date: 2022-12-09

Lead Sponsor: Intima Bioscience, Inc.

Target Recruit Count: 70

Registration Number: NCT05566223

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy